旧金山—根据最近的SEC文件披露，Hims & Hers Health, Inc.（纽交所代码：HIMS）的首席商务官Michael Chi最近执行了一系列涉及公司A类普通股的股票交易。 11月11日，Chi以每股24.77美元的价格出售了7,259股Hims & Hers Health股票，总计179,805美元。这次出售是根据Chi于2024年3月1日采用的10b5-1规则预先制定的交易计划进 ...

旧金山——根据最近向美国证券交易委员会提交的文件，Hims & Hers Health, Inc.（纽约证券交易所代码：HIMS）的首席法务官Boughton Soleil出售了部分公司A类普通股。这笔交易发生在11月12日，涉及以每股26.46美元的价格出售2,338股股票，总计约61,863美元。 在此次出售 ...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Shares of Hims & Hers Health (NYSE: HIMS) have been on fire over the past year, but they're not expensive by most valuation ...

智通财经获悉，远程医疗平台公司Hims & Hers Health(HIMS.US)首席执行官Andrew Dudum表示，该公司正准备在2025年推出诺和诺德(NVO.US)的旧版GLP-1减肥疗法liraglutide的非专利版本。liraglutide分别以Victoza和Saxenda的形式销售，用于治疗糖尿病和肥胖症。在2024年上半年，liraglutide为这家丹麦制药商带来 ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

智通财经获悉，远程医疗平台公司Hims & Hers Health(HIMS.US)首席执行官Andrew Dudum表示，该公司正准备在2025年推出诺和诺德(NVO.US)的旧版GLP-1... 智通财经 ...

Hims & Hers is revolutionizing telehealth and wellness for millennials and Gen Z with rapid revenue growth and positive net ...